Program
nbm-t-bmx-os 01
Its studies are mostly in Brain Neoplasms · Neoplasms, led by Novelwise Pharmaceutical.
Furthest: phase 2, since Aug 11, 20232 company-led studies, 2 open or runningNext primary completion: May 30, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novelwise Pharmaceutical | 22 open or running | phase 2since Aug 11, 2023 | Aug 11, 2023 | May 30, 2028phase 2 · NCT06012695 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 11, 2023First study: phase 2 study in NeoplasmsFirst studyNCT06012695 · 79 planned · Taiwan
- Apr 24, 2026Phase 2 study in Brain NeoplasmsNCT07569042 · 15 planned · Taiwan
Ahead
- May 30, 2028Primary completion: phase 2 study in NeoplasmsNCT06012695
- Sep 30, 2029Primary completion: phase 2 study in Brain NeoplasmsNCT07569042
TargetBeta
HDAC8 →read by rule
“An orally bioavailable inhibitor of histone deacetylase (HDAC) type 8 (HDAC8; HDAC-8), ”NCIt, by rule
Other programs on HDAC8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| givinostatrule | Italfarmaco | phase 3 | 23 |
| givinostat hydrochloriderule | Italfarmaco | phase 2 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07569042Brain Neoplasms · Taiwan | 2 | Recruiting | Sep 30, 2029 | 15 |
| NCT06012695Neoplasms · Taiwan | 2 | Recruiting | May 30, 2028 | 79 |
How it is read
Names in the registry
- “NBM-BMX Capsule”, 2 entries
Conditions, from the studies’ own filings
- Brain Neoplasms, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.